Recent studies into retatrutide, a dual activator for GLP-1 and GIP receptors, are showing promising effects in treating obesity and diabetes non-insulin-dependent disease. Preclinical information suggest a distinct https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/